Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

What They’re Saying about the Medicare Part B Demo

health care, medicine

Back in March, CMS’s Center for Medicare and Medicaid Innovation (CMMI) proposed a sweeping demonstration project that would dramatically lower the rate at which many providers are reimbursed for medicines administered under Medicare Part B. Medicare Part B  covers drugs administered in a provider setting, and patients served under the program include those fighting diseases such as cancer, multiple sclerosis, macular degeneration, rheumatoid arthritis and primary immunodeficiency diseases – those most in need of the Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , ,

NORD President: Congress must act now to help 15 million sick children

lab_tech

Writing in The Hill, National Organization for Rare Disorders (NORD) President and CEO Peter Saltonstall called upon Congress to act swiftly to maintain an important program encouraging research into treatments for rare pediatric diseases. The Rare Pediatric Priority Review Voucher (PRV) Program is set to expire at the end of the month, unless Congress reauthorizes it. Saltonstall writes: Developing therapies for people with rare diseases is incredibly difficult. Rare diseases are scientifically and medically complex, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biotech Solutions for Zika

BIO_2016

The Zika virus epidemic continues to rage on. Just today, the WHO advised people in Zika affected countries (much of Latin America and the Caribbean) to consider delaying pregnancy, and emerging evidence suggests a broader range of possible complications for babies born to women infected with the virus than was first thought. Solutions are urgently needed, and biotechnology companies are hard at work to contribute. During a Wednesday at the 2016 BIO International Convention, attendees heard from Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , ,

BIO Releases Largest Study Ever on Clinical Development Success Rates

new-bio-logo

On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success. “This study provides a wealth of information about drug development success rates Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Morning Consult: Medicare’s Deadly Cancer Care Gamble

new-bio-logo

Today in Morning Consult, cancer survivor and health economist Jennifer Hinkel writes about the threat posed to cancer patients by CMS’s proposed Medicare Part B drug payment model: Who will bear the most significant burden? It will be the poorest, oldest, and least educated patients who will struggle to understand whether they and their doctors have been assigned to the “experimental arm” of this reimbursement research trial. These Medicare beneficiaries will be the unwitting subjects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,